Tygacil (tigecycline): Label Change – Increased Mortality Risk

Audience: Infectious Disease, Critical Care Medicine, Internal Medicine ISSUE: FDA reminded healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of…



No related posts.